Amgen To Defend Neulasta Against Biosimilars With New Delivery System
This article was originally published in The Pink Sheet Daily
Executive Summary
A novel on-body delivery system for Neulasta, pending at FDA for approval, could ease administration for patients and help Amgen protect its blockbuster neutropenia franchise against biosimilars.